Last updated: February 16, 2026
Market Overview for NDC 53746-0361
ND C 53746-0361 is identified as Zepzelca (lurbinectedin), a chemotherapy agent approved for treatment of metastatic small cell lung cancer (SCLC). The drug was approved by the FDA on June 1, 2020, under accelerated approval, targeting adult patients who have progressed on platinum-based chemotherapy.
Market Size and Demand Drivers
Current Indications
- Primarily for adult patients with metastatic small cell lung cancer.
- Usage is limited to specialized oncology settings.
Market Penetration
- The SCLC market is relatively small compared to other lung cancer types, with approximately 30,000 new cases annually in the U.S.
- Zepzelca's market penetration remains limited due to competition from existing chemotherapies and emerging immuno-oncology treatments.
Existing Competition
- Top competitors include topoisomerase inhibitors like topotecan and etoposide.
- Emerging therapies, including checkpoint inhibitors (e.g., atezolizumab, durvalumab), are gaining FDA approval and expanding treatment options.
Market Growth Expectations
- The global small cell lung cancer treatment market was valued at roughly $544 million in 2022 (source: GlobalData).
- CAGR projected around 8-10% through 2028, driven by:
- Increased diagnosis rates.
- Off-label adoption.
- Expansion into earlier lines of therapy.
Price Projections
Current Pricing
- Typical wholesale acquisition cost (WAC) per treatment cycle ranges from $15,000 to $21,000.
- Exact pricing varies based on dosage and treatment regimen, typically around $150 to $200 per mg.
- Cost per patient per course is estimated at approximately $75,000 to $100,000, depending on patient size and number of cycles.
Future Pricing Trends
- Price stabilization is expected due to the nature of chemotherapies, which face pricing pressure from biosimilar development and hospital negotiations.
- As Zepzelca gains broader approval and potential expansion into earlier lines, prices could marginally increase to reflect higher demand, but competitive pressures and healthcare cost containment efforts may limit significant hikes.
Reimbursement Landscape
- Reimbursement largely through Medicare, Medicaid, and private insurers.
- Reimbursement rates are aligned with negotiated prices; coverage for off-label indications remains limited.
Market Revenue Projections (2023-2028)
| Year |
Estimated Revenue (USD millions) |
Key Assumptions |
| 2023 |
150 |
Limited uptake post-launch; hospital formularies adapting |
| 2024 |
225 |
Slight increase with more line extensions |
| 2025 |
300 |
Broader adoption in second-line settings |
| 2026 |
400 |
Entry into earlier treatment lines and geographic expansion |
| 2027 |
500 |
Competitive pressures increase; price stabilization |
| 2028 |
550 |
Market saturation; modest growth |
Strategic Factors & Risks
- Regulatory approvals: Future approvals for broader indications can significantly influence sales.
- Pricing pressure: Biosimilar competition could emerge, especially outside the U.S.
- Clinical efficacy: Confirmatory trials and post-approval studies vital to expanding use.
- Market penetration: Adoption depends on oncologists’ familiarity and hospital formulary decisions.
Key Takeaways
- NDC 53746-0361 (Zepzelca) has a niche market with growth potential driven by rising SCLC cases and potential label expansion.
- Current wholesale prices hover around $15,000-$21,000 per cycle, with estimated annual revenues of $150M initially, rising to over $500M by 2028.
- Competitive pressures, biosimilar development, and evolving treatment standards pose market risks.
FAQs
1. What is the primary indication for NDC 53746-0361?
It treats metastatic small cell lung cancer in adult patients who have progressed following platinum-based chemotherapy.
2. How does the current market size compare to other oncology drugs?
Its market is smaller than major lung cancer treatments, such as immunotherapies, but sizable within niche small cell lung cancer therapies.
3. Are biosimilars likely to impact the pricing of Zepzelca?
While biosimilars are less common for chemotherapies than biologics, potential future entrants could exert downward pricing pressure.
4. What are the key drivers for growth in the Zepzelca market?
Expansion into earlier treatment lines, increased diagnosis rates, and geographic expansion.
5. What are regulatory challenges facing Zepzelca?
Confirmatory trials are needed for broader indications; off-label use remains limited by payers.
Sources
- FDA Approval Documentation, 2020.
- GlobalData, Small Cell Lung Cancer Market Report, 2022.
- manufacturer’s label and pricing data.
- Industry analysis reports, 2023.
